1. From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis
Ann Intern Med. 2016;164(11): doi: /M
Figure Legend:
† Comorbid condition restrictions were end-stage renal disease, end-stage liver disease, cancer, new-onset diabetes after transplant, or a cardiovascular event within 3 mo (such as acute coronary syndrome, acute myocardial infarction, post–coronary artery bypass graft surgery, or drug-eluting stents).
Date of download: 10/12/2017
Copyright © American College of Physicians. All rights reserved.

2. From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis
Ann Intern Med. 2016;164(11): doi: /M
Figure Legend:
All differences for HbA1c are absolute percentage-point differences. BL = baseline; DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; HbA1c = hemoglobin A1c; Met = metformin; PLE = profile likelihood estimate; SGLT-2 = sodium–glucose cotransporter 2; SU = sulfonylurea; TZD = thiazolidinedione.
Date of download: 10/12/2017
Copyright © American College of Physicians. All rights reserved.

3. From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis
Ann Intern Med. 2016;164(11): doi: /M
Figure Legend:
BL = baseline; DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; Met = metformin; PLE = profile likelihood estimate; SGLT-2 = sodium–glucose cotransporter 2; SU = sulfonylurea; TZD = thiazolidinedione; wt = weight.
Date of download: 10/12/2017
Copyright © American College of Physicians. All rights reserved.

4. From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis
Ann Intern Med. 2016;164(11): doi: /M
Figure Legend:
Relative risk for hypoglycemia shown by ranges in absolute RDs across study groups and as pooled odds ratios. DPP-4 = dipeptidyl peptidase-4; Met = metformin; PLE = profile likelihood estimate; RD = risk difference; SGLT-2 = sodium–glucose cotransporter 2; SU = sulfonylurea; TZD = thiazolidinedione.
Date of download: 10/12/2017
Copyright © American College of Physicians. All rights reserved.

5. From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis
Ann Intern Med. 2016;164(11): doi: /M
Figure Legend:
DPP-4 = dipeptidyl peptidase-4; GI = gastrointestinal; GLP-1 = glucagon-like peptide-1; Met = metformin; RD = risk difference; SGLT-2 = sodium–glucose cotransporter 2; SU = sulfonylurea; TZD = thiazolidinedione.
Date of download: 10/12/2017
Copyright © American College of Physicians. All rights reserved.